Marina Zhuravleva

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6797248/publications.pdf

Version: 2024-02-01

1478505 1281871 26 130 11 6 citations h-index g-index papers 31 31 31 99 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Meta-analytical evaluation of the clinical efficacy of a complex metabolic neuroprotector in patients with chronic cerebral ischemia. Antibiotiki I Khimioterapiya, 2022, 66, 39-53.	0.6	2
2	The Impact of Combination Therapy with Rivaroxaban and Acetylsalicylic Acid in Patients with Coronary Heart Disease on the Achievement of the Target for Reducing Mortality from Cardiovascular Diseases of the Federal Project "Fight against Cardiovascular Diseases". Rational Pharmacotherapy in Cardiology, 2022, 18, 56-66.	0.8	1
3	Consensus expert opinion on key items in planning and designing clinical trials in geriatric patients. Russian Journal of Geriatric Medicine, 2022, , 398-402.	0.6	O
4	Effect of dapagliflozin therapy on achieving cardiovascular mortality target indicators in patients with heart failure. Russian Journal of Cardiology, 2022, 26, 4800.	1.4	2
5	Evaluation of the effect of the use of the drug ticagrelor in patients with acute coronary syndrome on achieving the target indicator "reduction of mortality from diseases of the circulatory system―in 2022-2024. Russian Journal of Cardiology, 2022, 26, 4819.	1.4	2
6	Changes in Post-COVID Syndrome Manifestations and Bulbar Conjunctival Angioscopy Results in a Patient Undergoing Treatment after Mild COVID-19. Safety and Risk of Pharmacotherapy, 2022, 10, 78-90.	0.2	0
7	Ademetionine treatment cost analysis of patients with intrahepatic cholestasis and non-alcoholic fatty disease. Kachestvennaya Klinicheskaya Praktika, 2022, , 41-52.	0.5	O
8	Antimicrobial Dispensing Practice in Community Pharmacies in Russia during the COVID-19 Pandemic. Antibiotics, 2022, 11, 586.	3.7	6
9	Evaluation of the Efficacy and Safety of Initial Empirical Antibiotic Therapy for Community-Acquired Pneumonia in Middle-Aged People. Safety and Risk of Pharmacotherapy, 2022, 10, 118-127.	0.2	O
10	Evaluation of the Effect of Comorbidity on the Efficacy and Safety of \hat{l}^2 -Lactam Antibiotics in Patients with Community-Acquired Pneumonia. Safety and Risk of Pharmacotherapy, 2022, 10, 96-109.	0.2	0
11	Assessment of Safety Signals for Aztreonam in Different Age Groups: National and International Drug Safety Monitoring. Safety and Risk of Pharmacotherapy, 2022, 10, 110-117.	0.2	O
12	INTERDISCIPLINARY CLINICAL PRACTICE GUIDELINES "MANAGEMENT OF OBESITY AND ITS COMORBIDITIES". Obesity and Metabolism, 2021, $18, 5-99$.	1.2	49
13	Major Aspects of Detection and Monitoring of Adverse Reactions Associated with Cephalosporin Antibiotic Treatment. Safety and Risk of Pharmacotherapy, 2021, 9, 34-42.	0.2	6
14	Study of Cases of Bacteremia with Gram-Negative Pathogens with Multiple and Extreme Antibiotic Resistance in Real Clinical Practice. Antibiotiki I Khimioterapiya, 2021, 66, 27-34.	0.6	4
15	Comparative Analysis of Drug Interactions with Antibacterial Agents in the Treatment of Community-Acquired Pneumonia. Safety and Risk of Pharmacotherapy, 2021, 9, 136-143.	0.2	1
16	Risk Factors and Characteristics of Adverse Reactions Associated with the Use of Beta-Lactam Antibiotics in Older Patients. Safety and Risk of Pharmacotherapy, 2021, 9, 128-135.	0.2	0
17	Expert consensus statement on the diagnosis and treatment of fulminant myocarditis in the context of the COVID-19 pandemic. Akademi $ ilde{A}^{\xi}$ Mediciny I Sporta, 2020, 1, 28-40.	0.1	4
18	Analysis of the drug prescription for obese patients in Moscow. Kachestvennaya Klinicheskaya Praktika, 2020, , 53-60.	0.5	0

#	Article	IF	CITATION
19	Effects of ticagrelor in patients with acute coronary syndrome on the targets of the national cardiovascular program. Russian Journal of Cardiology, 2020, 25, 3931.	1.4	4
20	Effect of ticagrelor in patients with acute coronary syndrome on the achievement of the targets of federal project on the prevention of cardiovascular diseases: 3-year perspective estimates. Russian Journal of Cardiology, 2020, 25, 4223.	1.4	0
21	Safety of Herbal Medicines: Clinical and Pharmacological Aspects. Safety and Risk of Pharmacotherapy, 2020, 8, 165-177.	0.2	4
22	Strategy and Control of Antimicrobial Therapy Program Implementation at the B.V. Petrovsky National Research Center of Surgery. Antibiotiki I Khimioterapiya, 2020, 65, 44-50.	0.6	0
23	Effect of dapagliflozin in patients with heart failure on reducing cardiovascular mortality in federal project on the prevention of cardiovascular diseases. Russian Journal of Cardiology, 2020, 25, 4142.	1.4	3
24	Topical Issues of Drug Safety, Possibilities of Improving of Pharmacovigilance. Safety and Risk of Pharmacotherapy, 2019, 7, 109-119.	0.2	16
25	Novel Possibilities in Pharmacotherapy of Patients With Chronic Heart Failure. Kardiologiya, 2018, 17, 88-95.	0.7	0
26	The role of excipients in determining the pharmaceutical and therapeutic properties of medicinal agents (Review). Pharmaceutical Chemistry Journal, 2009, 43, 230-234.	0.8	12